Kodiak Sciences has patented a method for treating eye disorders, specifically wet age-related macular degeneration, using an anti-VEGF antibody conjugate. Administering three loading doses extends the therapeutic effect for at least 12 weeks, offering a less frequent treatment option. GlobalData’s report on Kodiak Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kodiak Sciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kodiak Sciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Kodiak Sciences's grant share as of April 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

Method of treating eye disorder with anti-vegf antibody conjugate

Source: United States Patent and Trademark Office (USPTO). Credit: Kodiak Sciences Inc

A recently granted patent (Publication Number: US11912784B2) discloses a method for treating eye disorders, specifically wet age-related macular degeneration (wAMD), using an anti-VEGF antibody conjugate. The method involves administering three loading doses of the conjugate to a subject, with the heavy chain of the antibody conjugate containing specific amino acid sequences and a phosphorylcholine containing polymer covalently bonded to it. The therapeutic result of the treatment is expected to last for at least 12 weeks after the final loading dose, with subsequent doses administered based on the outcome of assessment tests for ocular health and function. The dosing schedule for subsequent doses is no more frequent than once a month, ensuring the effective treatment of the eye disorder.

Furthermore, the patent outlines various claims related to the method, including the duration of the therapeutic result lasting up to 20 weeks past the final loading dose, the administration of subsequent doses at specific time intervals, and the specific structure of the antibody conjugate. The method aims to modify the disease in a beneficial manner to the subject, with improved visual acuity, reduced retinal thickness, and other positive outcomes. The administration of the anti-VEGF antibody conjugate via intravitreal injection is highlighted, emphasizing the targeted delivery of the treatment for optimal results. Overall, the patent provides a detailed and structured approach to treating eye disorders, particularly wAMD, with a focus on long-lasting therapeutic effects and personalized dosing schedules based on individual assessment outcomes.

To know more about GlobalData’s detailed insights on Kodiak Sciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies